Next Article in Journal
DNA Repair Biosensor-Identified DNA Damage Activities of Endophyte Extracts from Garcinia cowa
Next Article in Special Issue
Inherent Beta Cell Dysfunction Contributes to Autoimmune Susceptibility
Previous Article in Journal
GSK3α: An Important Paralog in Neurodegenerative Disorders and Cancer
Open AccessFeature PaperReview

Beta Cell Therapies for Preventing Type 1 Diabetes: From Bench to Bedside

1
Department of Physiology and Pathophysiology, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 3P4, Canada
2
Children’s Hospital Research Institute of Manitoba, Winnipeg, MB R3E 3P4, Canada
*
Author to whom correspondence should be addressed.
Biomolecules 2020, 10(12), 1681; https://doi.org/10.3390/biom10121681
Received: 20 November 2020 / Revised: 9 December 2020 / Accepted: 14 December 2020 / Published: 16 December 2020
Type 1 diabetes (T1D) is a chronic metabolic disease characterized by insulin deficiency, generally resulting from progressive autoimmune-mediated destruction of pancreatic beta cells. While the phenomenon of beta cell autoimmunity continues to be an active area of investigation, recent evidence suggests that beta cell stress responses are also important contributors to disease onset. Here we review the pathways driving different kinds of beta cell dysfunction and their respective therapeutic targets in the prevention of T1D. We discuss opportunities and important open questions around the effectiveness of beta cell therapies and challenges for clinical utility. We further evaluate ways in which beta cell drug therapy could be combined with immunotherapy for preventing T1D in light of our growing appreciation of disease heterogeneity and patient endotypes. Ultimately, the emergence of pharmacologic beta cell therapies for T1D have armed us with new tools and closing the knowledge gaps in T1D etiology will be essential for maximizing the potential of these approaches. View Full-Text
Keywords: pancreatic beta cells; type 1 diabetes; apoptosis; senescence; immunotherapy pancreatic beta cells; type 1 diabetes; apoptosis; senescence; immunotherapy
Show Figures

Figure 1

MDPI and ACS Style

Brawerman, G.; Thompson, P.J. Beta Cell Therapies for Preventing Type 1 Diabetes: From Bench to Bedside. Biomolecules 2020, 10, 1681. https://doi.org/10.3390/biom10121681

AMA Style

Brawerman G, Thompson PJ. Beta Cell Therapies for Preventing Type 1 Diabetes: From Bench to Bedside. Biomolecules. 2020; 10(12):1681. https://doi.org/10.3390/biom10121681

Chicago/Turabian Style

Brawerman, Gabriel; Thompson, Peter J. 2020. "Beta Cell Therapies for Preventing Type 1 Diabetes: From Bench to Bedside" Biomolecules 10, no. 12: 1681. https://doi.org/10.3390/biom10121681

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop